(Z)-endoxifen
Metastatic Breast Cancer
Key Facts
About Atossa Therapeutics
Atossa Therapeutics is a focused, clinical-stage biopharmaceutical company with a singular mission to transform breast cancer care through its proprietary compound, (Z)-endoxifen. Its strategy centers on developing this highly potent SERM across multiple high-need breast cancer indications, including metastatic disease, representing a high-conviction, platform-like approach with a single multi-indication asset. The company operates as a lean, development-focused entity, channeling resources into clinical trials designed to demonstrate the efficacy and safety of its novel candidate.
View full company profileAbout Atossa Therapeutics
Atossa Therapeutics is a focused, clinical-stage biopharmaceutical company with a singular mission to transform breast cancer care through its proprietary compound, (Z)-endoxifen. Its strategy centers on developing this highly potent SERM across multiple high-need breast cancer indications, including metastatic disease, representing a high-conviction, platform-like approach with a single multi-indication asset. The company operates as a lean, development-focused entity, channeling resources into clinical trials designed to demonstrate the efficacy and safety of its novel candidate.
View full company profileTherapeutic Areas
Other Metastatic Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| ZetaMAST (Zeta-MBC-005) | Zetagen Therapeutics | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| Vectorized-VX-765 | Atlanthera | Research |
| AURORA 2 Project Collaboration | Seqalis | Phase 2 |
| BPI-1178 (Eciruciclib) | Beta Pharma | Phase 3 |
| Herzuma® | Celltrion | Marketed |
| Eftilagimod alfa (efti) | Immutep | Phase IIb |
| Bria-IMT™ + CPI | BriaCell Therapeutics | Phase 3 |
| Bria-OTS™ (Bria-BRES™) | BriaCell Therapeutics | Phase 1/2 |